[{"orgOrder":0,"company":"Concord Biotech","sponsor":"Lupin Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Mycophenolate Mofetil","moa":"||IMPDH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Concord Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concord Biotech \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Concord Biotech \/ Lupin Ltd"}]

Find Clinical Drug Pipeline Developments & Deals by Concord Biotech

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : Mycophenolate Mofetil Tablets are indicated for the prophylaxis of organ rejection in recipients of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants.

                          Product Name : Mofecon

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          June 08, 2020

                          Lead Product(s) : Mycophenolate Mofetil,Corticosteroids,Cyclosporine

                          Therapeutic Area : Nephrology

                          Highest Development Status : Approved FDF

                          Sponsor : Lupin Ltd

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank